BRIEF-Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study At Society For Immunotherapy Of Cancer

Reuters
Nov 08, 2024

Nov 8 (Reuters) - Kineta Inc :

* KINETA UPDATES KVA12123 CLINICAL RESULTS FROM ONGOING PHASE 1/2 VISTA101 STUDY AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (2024)

* KINETA INC - FAVORABLE TOLERABILITY AND TOXICITY PROFILE IN BOTH ARMS

Source text: Further company coverage:

(Reuters.Briefs@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10